Читать книгу Biologics, Biosimilars, and Biobetters - Группа авторов - Страница 49

Evergreening refers to the use of various strategies for patent extension, of innovator biologics as also occurs for SMD innovator drugs to delay the introduction of their SMD generics. Among other outcomes, evergreening may limit timely availability of biosimilars and affect their price.⁸⁰